SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Recycling symbol with arrows made of brown paper on a green textured background. Top view.
Policy
FDA turns to old drugs to address new diseases, persistent medical needs
The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.
May 12, 2026
 · 
2 min read
 · 
Tristan Manalac
Rainy season, heavy rain, Rain drops background, Nature rainfall with storm clouds
Earnings
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed upon with CMOs and prompting the cancellation of an in-house investment.
May 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
business
Government
Makary’s reported FDA removal could be ‘broad positive’ for biopharma
The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head Vinay Prasad highlights the severe turnover rates at the highest rungs of leadership at the health department.
May 11, 2026
 · 
3 min read
 · 
Tristan Manalac
Modern collage with halftone hand holding pencil and drawing check mark. Confirmation. Concepts of agreement and choice
Approvals
Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher
Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review.
May 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Sponsored by Sino Biological
Advances in RSV Vaccine Research and Development
Epidemiology, Next-Generation Vaccine Platforms, and the Critical Role of Prefusion F Antigens in RSV Research
May 11, 2026
 · 
7 min read
Male with bandage repaired heart shape. Move on or forget and forgive, open for new relationship, heal heart broken or divorce and relationship problem.
Cardiovascular
Merck, Amgen double down on bad cholesterol to vanquish number 1 killer
New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on maintaining low levels of two key lipoproteins. Big pharma is all in, looking to improve on the standard statins to help vanquish America’s number one killer: heart disease.
May 11, 2026
 · 
6 min read
 · 
Ben Hargreaves
Conceptual image of crumpled paper balls as steps leading to a light bulb, symbolizing failure as part of the creative or problem-solving journey toward success
Complete response letters
Published FDA rejections point to manufacturing, data gaps as key stumbling blocks
The FDA’s decision last year to make complete response letters public provides new insight into why therapies sometimes fail to get the regulatory greenlight. Analysts say the information could help sponsors refine their regulatory strategies.
May 11, 2026
 · 
8 min read
 · 
Tristan Manalac
Businessman carrying a stopwatch on a progress bar illustrating last minute deadline to complete a business project
Alzheimer’s disease
Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi. The new target action date is on Aug. 24.
May 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VI
Manufacturing
Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site
Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.
May 8, 2026
 · 
1 min read
 · 
Gabrielle Masson
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS